Sanofi-Genzyme BioVentures1, a corporate venturing unit of France-based healthcare company Sanofi Aventis, and Ireland-based pharmaceutical company Shire are joined by a large crowd of investors in the series B for the rare genetic disorder treatment company.

CMU-backed Medical robotics firm Medrobotics has secured $33.6m in a series D round.

US-based chemical maker Dupont has bought the right to BP Alternative Energy Ventures and DSM Venturing-backed Verdezyne's enzyme technology for an undisclosed amount.

SR One and Oxbridge Biotech Roundtable has launched OneStart, a $163,000 prize for medical technology entrepreneurs.

US-based biopharmaceutical company Regado Biosciences secures $51m in Series E funding from investors including RusnanoMedInvest and Baxter Ventures, a corporate venturing unit of Baxter Healthcare.

The TPG Biotech-backed hospital safety company raises more capital.

The $200m corporate venturing unit of Baxter International, Baxter Ventures, leads a $38m B round into Naurex, a US-based drug developer which has received technologies from Northwestern University.

TPG Biotech follows on investing in drug development company Trevi Therapeutics, which shares its name with the famous Trevi fountain in Rome (pictured), after backing the company's seed round.

Medical device company Cardiosonic, who are developing technology for treating hypertension, has raised $6.1m as part of a planned $16.1m series B financing, from an undisclosed strategic investor and Shmuel Almagor.